Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
| Autor: | Sibylle C. Mellinghoff, Philipp Köhler, Hans H. Hirsch, Marie von Lilienfeld-Toal, Maria Rüthrich, Michael Sandherr, Rosanne Sprute, Enrico Schalk, Nicola Giesen, Marcus Hentrich, Gernot Beutel, Oliver A. Cornely, Michael Koldehoff, Michael von Bergwelt-Baildon, Catherina Lueck, Bernhard Wörmann, Yascha Khodamoradi, H.-H. Wolf |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Pneumonia Viral coronavirus Medizin Antineoplastic Agents German Betacoronavirus 03 medical and health sciences 0302 clinical medicine Germany Neoplasms Internal medicine Health care Pandemic cancer Humans Medicine haematological malignancy Pandemics Societies Medical Original Research Hematology SARS-CoV-2 business.industry COVID-19 Disease Management Evidence-based management Guideline Prognosis language.human_language 030104 developmental biology Infectious disease (medical specialty) Evidence-Based Practice 030220 oncology & carcinogenesis Practice Guidelines as Topic language Coronavirus Infections business guideline Delivery of Health Care |
| Zdroj: | European Journal of Cancer |
| ISSN: | 0959-8049 |
| Popis: | Since its first detection in China in late 2019 the novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 continue to have a major impact on global health care and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria. Highlights • Cancer patients are vulnerable to SARS-CoV-2 infection and severe COVID-19. • Comprehensive management strategies are required in care for cancer patients. • Evidence-based recommendations help clinicians make informed treatment decisions. • Providing state-of-the-art cancer care is possible during COVID-19 pandemic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect